Literature DB >> 7173306

Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism.

R Axelsson, E Mårtensson, C Alling.   

Abstract

The blood chemistry and clinical pharmacokinetics of thioridazine and its metabolites, side-chain sulphoxide, side-chain sulphone and ring sulphoxide, were studied in 31 alcoholics and were compared with values in 17 thioridazine-treated controls without alcoholism. Pathological blood chemistry values, including abnormal liver function and protein concentrations, were common among the alcoholics. In relation to dosage, the majority had a low serum concentration of thioridazine and at a given concentration of thioridazine they had high serum concentrations of its metabolites. Positive intercorrelations were found between pathological liver function tests, prolonged serum half-life and increased serum concentration of thioridazine. The free fractions of thioridazine, side-chain sulphoxide and ring sulphoxide were significantly higher and those of the side-chain sulphone lower in the alcoholics than in the controls. The free fractions of side-chain and ring sulphoxide were significantly increased in patients with a low concentration of alpha 1-acid glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173306     DOI: 10.1007/bf00613621

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients.

Authors:  G Nyberg; R Axelsson; E Mårtensson
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Quantitative determination of thioridazine and nonconjugated thioridazine metabolites in serum and urine of psychiatric patients.

Authors:  E Mårtensson; G Nyberg; R Axelsson; K Serck-Hansen
Journal:  Curr Ther Res Clin Exp       Date:  1975-11

4.  Serum concentration and elimination from serum of thioridazine in psychiatric patients.

Authors:  R Axelsson; E Mårtensson
Journal:  Curr Ther Res Clin Exp       Date:  1976-02
  4 in total
  2 in total

1.  Binding of thioridazine and thioridazine metabolites to serum proteins. An in vitro study.

Authors:  G Nyberg; E Mårtensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

2.  Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.

Authors:  Sokbom Kang; Seung Myung Dong; Boh-Ram Kim; Mi Sun Park; Barry Trink; Hyun-Jung Byun; Seung Bae Rho
Journal:  Apoptosis       Date:  2012-09       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.